Importantly, disruption of either JNK activity or expression of SPP1 or TNC sensitizes mammary tumors and metastases to chemotherapy, suggesting a potentially useful combinatorial treatment strategy to target metastatic breast cancer. The gene discussed is TNC; the disease is breast carcinoma.